Dapagliflozin/Pioglitazone
- Generic Name
- Dapagliflozin/Pioglitazone
A Phase IV Clinical Study to Compared the Efficacy and Safety of Switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes
Phase 4
Not yet recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 204
- Registration Number
- NCT06972732
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seocho District, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath